Our strict production procedures have helped us reach a respectable position in the industry
Chronic pain often stems from inflammation and oxidative damage to tissues
Your pee probably isnt on that list
HPN-07 scavenges free radicals, inhibits iNOS, COX-2 and NF-B, and reduces excitotoxicity 28,29
What we know so far: Coverage is forming - Foundayo was FDA approved April 1, 2026 Plan type matters - Large employers may have more flexibility Self-pay is affordable - $149-$349/month via LillyDirect (vs $1,000+ for injectable GLP-1s) Why this is good news Even without insurance coverage, Foundayo is one of the most affordable GLP-1 options available
Pfizer terminated lotiglipron in October 2023 due to dose-dependent liver enzyme elevations, and subsequently discontinued danuglipron in April 2025 after a single case of potential drug-induced liver injury was identified in a dose-optimization study